Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vancomycin vs Placebo in Persistently Febrile Neutropenic Patients
NCT00003805Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 1997
- Primary completion
- Jun 2000
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in febrile neutropenia (FN) comparing Vancomycin Arm with Placebo Arm (2 arms). Primary endpoint: Time to defervescence at 28 days. Started Nov 1997; status: completed.
02
Drugs
vancomycin
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT00003805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003805.